History
2016
CHIGENOVO was founded to provide one-stop solutions for the diagnosis and treatment of inherited eye diseases
2018
Received angel investment and initiated the productization process of ophthalmic gene therapy
2020
Received Pre-A investment to accelerate the commercialization processes of pipelines
2021
ZVS101e injection received FDA orphan drug designation and started clinical trials
2022
Received A-round investment to accelerate project R&D and clinical trials ZVS101e injection obtained IND approvals from China NMPA and U.S. FDA ZVS203e injection received FDA orphan drug designation
2023
Received A+ round investment The Phase I/II clinical trial of ZVS101e injection was completed for all participants ZVS203e injection started IIT clinical trial and submitted IND application in US and China ZVS203e injection obtained IND approvals from the U.S. FDA
2024
ZVS203e injection obtained IND approvals from China NMPA ZVS101e injection received Breakthrough Therapy designation from China NMPA Initiated ZVS101e phase III clinical trial
CHIGENOVO Co., Ltd. is an ophthalmic gene therapy company, a national high-tech enterprise focusing on genetic diagnosis of genetic eye diseases and the development of gene therapy drugs. It is committed to providing "one-stop" services for patients with genetic eye diseases.
HUATAO GROUP
Contact us
Telephone:400-6006223 010-82071936
Website:en.chinagene.cc
Address: Floor 4, Area D, Building 1, No.27 Life Garden Road, Zhongguancun Life Science Park, Changping District, Beijing
WeChat subscription account
